Kamp Fires

  • by: |
  • 03/06/2007
Per my post from yesterday ("Giving EBM the Boot"), our friend John Kamp offers the following:

Why indeed?

As your blog item notes, we better stop "saving" money by restricting formularies and delaying treatment, or there may be fewer lives to save and less money to treat the survivors.

Let me elaborate with one example, Type II diabetes, a condition I follow closely because I have it.

I spent much of the weekend catching up on the new research presented late last year at the World Diabetes Conference in Capetown, South Africia, supporting more aggressive treatment of Type II diabetes.

The research results are exciting. First, earlier and more aggressive treatment will improve blood sugar control and delay the progression of the disease to where becomes ever more difficult to treat and to where complications proliferate. Second, new drugs and new ways to deliver existing drugs provide exciting evolutionary, though not revolutionary, advances. Recently approved and promising new drugs could delay progression of the disease for five to ten years. That could well mean that a 60 year old like me may never go blind, lose a foot, become impotent, require a liver transplant, have a premature heart attack, or face many of the other common complications of this dreaded, deadly disease.

Avoiding these things saves a lot of money in the long run, but requires time, attention and money. Right now -- not a few years from now -- I, my health plan, my doctor and the goverment must focus on more aggressive treatment. That requires pain and money.

For me, it means a significant personal committtment, including:

1. even more aggressive diet and exercise,
2. careful adherence to drug regimines, and
3. giving myself shots of insulin or insulin boosters.


For my doctor, it means education and monitoring much of which is not fully compensated.


For my health care plan and the government, it means spending more money today on treatment and drugs.


For me today's pains are worth the investment. I will work hard with my doctors and my payment partners to keep me healthy and make the investments needed. I will make up any shortfall from the others if needed. I'm fortunate enough to have the means and committment to do so.

Meanwhile, medical policy makers who review this new research must make a similar committment, and lead us to find the means to act on it.

Time is short. We are looking down the barrel of an epidimic of Type II diabetes that may dwarf the personal and social costs of the treatment of things like AIDS and cancer. Unfortunately, denial is the all too common reaction to the social danger of diabetes today.

Right now, medical policy makers must stop denying the cost and trouble of treating Type II diabetes. We must mobilize health care professionals, patients and government, take advantage of existing and developing science, and take a much more aggressive stance.

Denial of treatment at today's pace will mame and kill our bodies and bankrupt our treasuries.

Enough already.

John -- keep those cards and letters coming.

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog